Back to Oncology
OncologyvCTCAE v5.0Evidence-Based

Immune-Related Adverse Events for Lung Toxicity - Pneumonitis

Grades severity of pneumonitis secondary to immune checkpoint inhibitor (ICPi) therapy based on Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 criteria. This standardized grading system evaluates respiratory symptoms, oxygen requirements, and functional impact to determine the severity of immune-mediated pneumonitis and guide clinical management decisions including ICPi therapy continuation, corticosteroid treatment, pulmonology consultation needs, and monitoring for life-threatening respiratory complications. ICPi-induced pneumonitis has an incidence of 2.7% for all-grade and 0.8% for high-grade pneumonitis in single-agent therapy. The calculator provides evidence-based management recommendations essential for oncologists, pulmonologists, and intensive care teams managing patients on immunotherapy.

Clinical Input Parameters

Clinical Assessment
Awaiting Parameters
grade
—grade
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Immune-Related Adverse Events for Lung Toxicity - Pneumonitis is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within oncology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

CTCAE grading based on symptom severity, functional impact, oxygen requirements, and radiographic extent: Grade 1: Asymptomatic with radiographic changes; Grade 2: Symptomatic limiting instrumental ADLs; Grade 3: Severe symptoms limiting self-care ADLs, oxygen indicated; Grade 4: Life-threatening respiratory compromise requiring urgent intervention

Clinical Pearls & Practice Notes

  • ICPi-induced pneumonitis has incidence of 2.7% for all-grade and 0.8% for high-grade pneumonitis
  • Higher incidence with combination immunotherapy compared to single-agent therapy
  • Onset typically occurs 2-24 weeks after treatment initiation (median 2.8 months)
  • CT chest is more sensitive than chest X-ray for detection of pneumonitis
  • Four main radiographic patterns: cryptogenic organizing pneumonia (COP), nonspecific interstitial pneumonia (NSIP), hypersensitivity pneumonitis (HP), and acute interstitial pneumonia/ARDS
  • Bronchoscopy should be performed to rule out infection, especially before starting immunosuppression
  • Grade 1-2: Outpatient management possible with close monitoring
  • Grade 3-4: Require hospitalization, often ICU care for Grade 4
  • Permanent ICPi discontinuation recommended for Grade 3-4 pneumonitis
  • Corticosteroids are first-line treatment for Grade 2-4 pneumonitis
  • Second-line agents for steroid-refractory cases: infliximab, mycophenolate mofetil, cyclophosphamide, IVIG
  • Monitor for opportunistic infections during immunosuppressive treatment
  • Pneumocystis jirovecii pneumonia (PCP) prophylaxis recommended for prolonged high-dose steroids

Evidence & Literature Citations

  1. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385.
  2. Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. J Natl Compr Canc Netw. 2020 Mar 1;18(3):230-241. doi: 10.6004/jnccn.2020.0012.
  3. Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2016 Dec 1;2(12):1607-1616. doi: 10.1001/jamaoncol.2016.2453.
  4. Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, et al. Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. J Clin Oncol. 2017 Mar 10;35(7):709-717. doi: 10.1200/JCO.2016.68.2005.

Score Interpretation Ranges

Grade 11 – 1 pts

Mild - Asymptomatic; clinical or diagnostic observations only

Grade 22 – 2 pts

Moderate - Symptomatic; limiting instrumental ADLs

Grade 33 – 3 pts

Severe - Limiting self-care ADLs; oxygen indicated

Grade 44 – 4 pts

Life-threatening - Life-threatening respiratory compromise; urgent intervention indicated

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.